A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 13 Aug 2015 Planned number of patients changed from 180 to 226, as reported by ClinicalTrials.gov.
- 04 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.